Gene and stem cell therapy in ischemic stroke

Toru Yamashita, Kentaro Deguchi, Shoko Nagotani, Tatsushi Kamiya, Koji Abe

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Possible strategies for treating ischemic stroke include neuroprotection (preventing injured neurons from undergoing apoptosis in the acute phase of cerebral ischemia) and stem cell therapy (the repair of disrupted neuronal networks with newly born neurons in the chronic phase of cerebral ischemia). First, we estimated the neuroprotective effect of glial cell line-derived neurotrophic factor (GDNF) by administration of GFNF protein. GDNF protein showed a direct protective effect against ischemic brain damage. Pretreatment of animals with adenoviral vector containing GDNF gene (Ad-GDNF) 24 h before the subsequent transient middle cerebral artery occlusion (MCAO) effectively reduced infarcted volume. Secondly, we studied the neuroprotective effect of a calcium channel blocker, azelnidipine, or a by-product of heme degradation, biliverdin. Both azelnidipine and biliverdin had a neuroprotective effect in the ischemic brain through their antioxidative property. Lastly, we developed a restorative stroke therapy with a bioaffinitive scaffold, which is able to provide an appropriate platform for newly born neurons. In the future, we will combine these strategies to develop more effective therapies for treatment of strokes.

Original languageEnglish
Pages (from-to)999-1002
Number of pages4
JournalCell Transplantation
Volume18
Issue number9
DOIs
Publication statusPublished - 2009

Fingerprint

Glial Cell Line-Derived Neurotrophic Factor
Cell- and Tissue-Based Therapy
Stem cells
Neuroprotective Agents
Stem Cells
Genes
Stroke
Biliverdine
Neurons
Brain Ischemia
Brain
Proteins
Middle Cerebral Artery Infarction
Calcium Channel Blockers
Cell death
Heme
Scaffolds
Byproducts
Calcium
Animals

Keywords

  • Adenoviral vector
  • Cerebral ischemia
  • Free radical
  • Neural stem cells
  • Scaffold

ASJC Scopus subject areas

  • Cell Biology
  • Transplantation
  • Biomedical Engineering

Cite this

Gene and stem cell therapy in ischemic stroke. / Yamashita, Toru; Deguchi, Kentaro; Nagotani, Shoko; Kamiya, Tatsushi; Abe, Koji.

In: Cell Transplantation, Vol. 18, No. 9, 2009, p. 999-1002.

Research output: Contribution to journalArticle

Yamashita, Toru ; Deguchi, Kentaro ; Nagotani, Shoko ; Kamiya, Tatsushi ; Abe, Koji. / Gene and stem cell therapy in ischemic stroke. In: Cell Transplantation. 2009 ; Vol. 18, No. 9. pp. 999-1002.
@article{80f8763646cd4d6894770ec6fd88428d,
title = "Gene and stem cell therapy in ischemic stroke",
abstract = "Possible strategies for treating ischemic stroke include neuroprotection (preventing injured neurons from undergoing apoptosis in the acute phase of cerebral ischemia) and stem cell therapy (the repair of disrupted neuronal networks with newly born neurons in the chronic phase of cerebral ischemia). First, we estimated the neuroprotective effect of glial cell line-derived neurotrophic factor (GDNF) by administration of GFNF protein. GDNF protein showed a direct protective effect against ischemic brain damage. Pretreatment of animals with adenoviral vector containing GDNF gene (Ad-GDNF) 24 h before the subsequent transient middle cerebral artery occlusion (MCAO) effectively reduced infarcted volume. Secondly, we studied the neuroprotective effect of a calcium channel blocker, azelnidipine, or a by-product of heme degradation, biliverdin. Both azelnidipine and biliverdin had a neuroprotective effect in the ischemic brain through their antioxidative property. Lastly, we developed a restorative stroke therapy with a bioaffinitive scaffold, which is able to provide an appropriate platform for newly born neurons. In the future, we will combine these strategies to develop more effective therapies for treatment of strokes.",
keywords = "Adenoviral vector, Cerebral ischemia, Free radical, Neural stem cells, Scaffold",
author = "Toru Yamashita and Kentaro Deguchi and Shoko Nagotani and Tatsushi Kamiya and Koji Abe",
year = "2009",
doi = "10.3727/096368909X471233",
language = "English",
volume = "18",
pages = "999--1002",
journal = "Cell Transplantation",
issn = "0963-6897",
publisher = "Cognizant Communication Corporation",
number = "9",

}

TY - JOUR

T1 - Gene and stem cell therapy in ischemic stroke

AU - Yamashita, Toru

AU - Deguchi, Kentaro

AU - Nagotani, Shoko

AU - Kamiya, Tatsushi

AU - Abe, Koji

PY - 2009

Y1 - 2009

N2 - Possible strategies for treating ischemic stroke include neuroprotection (preventing injured neurons from undergoing apoptosis in the acute phase of cerebral ischemia) and stem cell therapy (the repair of disrupted neuronal networks with newly born neurons in the chronic phase of cerebral ischemia). First, we estimated the neuroprotective effect of glial cell line-derived neurotrophic factor (GDNF) by administration of GFNF protein. GDNF protein showed a direct protective effect against ischemic brain damage. Pretreatment of animals with adenoviral vector containing GDNF gene (Ad-GDNF) 24 h before the subsequent transient middle cerebral artery occlusion (MCAO) effectively reduced infarcted volume. Secondly, we studied the neuroprotective effect of a calcium channel blocker, azelnidipine, or a by-product of heme degradation, biliverdin. Both azelnidipine and biliverdin had a neuroprotective effect in the ischemic brain through their antioxidative property. Lastly, we developed a restorative stroke therapy with a bioaffinitive scaffold, which is able to provide an appropriate platform for newly born neurons. In the future, we will combine these strategies to develop more effective therapies for treatment of strokes.

AB - Possible strategies for treating ischemic stroke include neuroprotection (preventing injured neurons from undergoing apoptosis in the acute phase of cerebral ischemia) and stem cell therapy (the repair of disrupted neuronal networks with newly born neurons in the chronic phase of cerebral ischemia). First, we estimated the neuroprotective effect of glial cell line-derived neurotrophic factor (GDNF) by administration of GFNF protein. GDNF protein showed a direct protective effect against ischemic brain damage. Pretreatment of animals with adenoviral vector containing GDNF gene (Ad-GDNF) 24 h before the subsequent transient middle cerebral artery occlusion (MCAO) effectively reduced infarcted volume. Secondly, we studied the neuroprotective effect of a calcium channel blocker, azelnidipine, or a by-product of heme degradation, biliverdin. Both azelnidipine and biliverdin had a neuroprotective effect in the ischemic brain through their antioxidative property. Lastly, we developed a restorative stroke therapy with a bioaffinitive scaffold, which is able to provide an appropriate platform for newly born neurons. In the future, we will combine these strategies to develop more effective therapies for treatment of strokes.

KW - Adenoviral vector

KW - Cerebral ischemia

KW - Free radical

KW - Neural stem cells

KW - Scaffold

UR - http://www.scopus.com/inward/record.url?scp=74049151610&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74049151610&partnerID=8YFLogxK

U2 - 10.3727/096368909X471233

DO - 10.3727/096368909X471233

M3 - Article

C2 - 19523331

AN - SCOPUS:74049151610

VL - 18

SP - 999

EP - 1002

JO - Cell Transplantation

JF - Cell Transplantation

SN - 0963-6897

IS - 9

ER -